Drug intelligence / Profile preview

brifentanil

Development stage: Unknown
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

Brifentanil is a synthetic opioid analgesic belonging to the fentanyl family. It is a potent, short-acting μ-opioid receptor agonist developed for use as an anesthetic adjunct or for pain management during surgical procedures. Like other fentanyl analogs, brifentanil acts primarily by binding to and activating the mu-opioid receptor in the central nervous system, resulting in analgesia, sedation, and respiratory depression. Brifentanil was investigated for its rapid onset and ultra-short duration of action similar to remifentanil; however, it has not been widely marketed or approved for clinical use.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on brifentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on brifentanil.

Explore the full profile